Literature DB >> 26000816

MicroRNAs and cell cycle of malignant glioma.

Qing Ouyang1, Lunshan Xu1, Hongjuan Cui2, Minhui Xu1, Liang Yi1.   

Abstract

The control of malignant glioma cell cycle by microRNAs (miRNAs) is well established. The deregulation of miRNAs in glioma may contribute to tumor proliferation by directly targeting the critical cell-cycle regulators. Tumor suppressive miRNAs inhibit cell cycle through repressing the expression of positive cell-cycle regulators. However, oncogenic miRNAs promote the cell-cycle progression by targeting cell-cycle negative regulators. Recent studies have identified that transcription factors had involved in the expression of miRNAs. Transcription factors and miRNAs are implicated in regulatory network of glioma cell cycle, the deregulation of these transcription factors might be a cause of the deregulation of miRNAs. Abnormal versions of miRNAs have been implicated in the cell cycle of glioma. Based on those, miRNAs are excellent biomarker candidates and potential targets for therapeutic intervention in glioma.

Entities:  

Keywords:  Glioma; biomarkers; cell cycle; microRNAs; transcription factor

Mesh:

Substances:

Year:  2015        PMID: 26000816     DOI: 10.3109/00207454.2015.1017881

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  13 in total

Review 1.  MicroRNA aberrations: An emerging field for gallbladder cancer management.

Authors:  Vishal Chandra; Jong Joo Kim; Balraj Mittal; Rajani Rai
Journal:  World J Gastroenterol       Date:  2016-02-07       Impact factor: 5.742

2.  Arctigenin, a natural lignan compound, induces G0/G1 cell cycle arrest and apoptosis in human glioma cells.

Authors:  Aisha Maimaitili; Zunhua Shu; Xiaojiang Cheng; Kadeer Kaheerman; Alifu Sikandeer; Weimin Li
Journal:  Oncol Lett       Date:  2016-12-08       Impact factor: 2.967

3.  Trophinin-associated protein expression correlates with shorter survival of patients with glioma: a study based on multiple data fusion analysis.

Authors:  Yong Sun; Zhen Dong Liu; Run Ze Liu; Xiao Yu Lian; Xing Bo Cheng; Yu Long Jia; Bin Feng Liu; Yan Zheng Gao; Xinjun Wang
Journal:  Mol Biol Rep       Date:  2022-06-16       Impact factor: 2.742

4.  LINC02308 promotes the progression of glioma through activating mTOR/AKT-signaling pathway by targeting miR-30e-3p/TM4SF1 axis.

Authors:  Xianfeng Gao; Xiaoya Wang; Huaiqiang He; Yang Cao
Journal:  Cell Biol Toxicol       Date:  2021-05-04       Impact factor: 6.691

5.  Downregulation of miR-16 via URGCP pathway contributes to glioma growth.

Authors:  Liang Hong; Ouyang Qing; Zhou Ji; Zhang Chengqu; Chen Ying; Cui Hao; Xu Minhui; Xu Lunshan
Journal:  Sci Rep       Date:  2017-10-18       Impact factor: 4.379

6.  Differential expression of miR16 in glioblastoma and glioblastoma stem cells: their correlation with proliferation, differentiation, metastasis and prognosis.

Authors:  R Tian; J Wang; H Yan; J Wu; Q Xu; X Zhan; Z Gui; M Ding; J He
Journal:  Oncogene       Date:  2017-06-19       Impact factor: 9.867

7.  A prognostic signature based on three non-coding RNAs for prediction of the overall survival of glioma patients.

Authors:  Junmin Xian; Quanzhong Zhang; Xiwen Guo; Xiankun Liang; Xinhua Liu; Yugong Feng
Journal:  FEBS Open Bio       Date:  2019-03-07       Impact factor: 2.693

8.  Identification of prognostic biomarkers in colorectal cancer using a long non-coding RNA-mediated competitive endogenous RNA network.

Authors:  Minjie He; Yan Lin; Yuzhen Xu
Journal:  Oncol Lett       Date:  2019-01-15       Impact factor: 2.967

9.  Long Non-Coding RNA GABPB1-AS1 Augments Malignancy of Glioma Cells by Sequestering MicroRNA-330 and Reinforcing the ZNF367/Cell Cycle Signaling Pathway.

Authors:  Xiulong Li; Hongfeng Wang
Journal:  Neuropsychiatr Dis Treat       Date:  2021-07-10       Impact factor: 2.570

10.  KDM2B overexpression correlates with poor prognosis and regulates glioma cell growth.

Authors:  Yiwei Wang; Jin Zang; Dongyong Zhang; Zhenxiang Sun; Bo Qiu; Xiaojie Wang
Journal:  Onco Targets Ther       Date:  2018-01-08       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.